p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and oncophenotype reversion in Rhabdomyosarcoma cells

Molecular Cancer

Volumn 4, Issue , 2005, Pages

  Ciccarelli, Carmela ^a   Marampon, Francesco ^a   Scoglio, Arianna ^b   Mauro, Annunziata ^a   Giacinti, Cristina ^b   De Cesaris, Paola ^a   Zani, Bianca M ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CYCLIN DEPENDENT KINASE INHIBITOR 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOD PROTEIN; MYOGENIN; SMALL INTERFERING RNA; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTOR; 1,3 BUTADIENE DERIVATIVE; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MITOGEN ACTIVATED PROTEIN KINASE; NITRILE; PHORBOL 13 ACETATE 12 MYRISTATE;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DATA ANALYSIS; EMBRYO CELL; ENZYME ACTIVATION; ENZYME INHIBITION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERTANT; RHABDOMYOSARCOMA; SARCOMA CELL; CELL PROLIFERATION; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PRENATAL DEVELOPMENT; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION;

BIOLOGICAL MARKERS; BUTADIENES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYOD PROTEIN; MYOGENIN; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; RHABDOMYOSARCOMA; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION, GENETIC;

EID: 29244459745     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-4-41     Document Type: Article

References (51)

1. Deshpande A, Sicinski P, Hinds PW: Cyclins and cdks in development and cancer: a perspective. Oncogene 2005, 24:2909-2915.
2. Dash BC and El Deiry WS: Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol.Biol. 2004, 280:99-161.
3. Reed SI: Control of the G1/S transition. Cancer Surv. 1997, 29:7-23.
4. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
5. Gartel AL and Tyner AL: Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp. Cell Res. 1999, 246:280-289.
6. Park JW, Jang MA, Lee YH, Passaniti A, Kwon TK: p53-independent elevation of p21 expression by PMA results from PKC-mediated mRNA stabilization. Biochem.Biophys.Res.Commun. 2001, 280:244-248.
7. Akashi M, Osawa Y, Koeffler HP, Hachiya M: p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization. Biochem.J. 1999, 337 (Pt 3):607-616.
8. Coleman ML, Marshall CJ, Olson MF: Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J. 2003, 22:2036-2046.
9. Ostrovsky O and Bengal E: The mitogen-activated protein kinase cascade promotes myoblast cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21WAF1 protein. J.Biol.Chem. 2003, 278:21221-21231.
10. Guo K, Wand J, Andres V, Smith RC, Walsh K: MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol.Cell Biol. 1995, 15:3823-3829.
11. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995, 267:1018-1021.
12. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ: p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995, 267:1024-1027.
13. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822.
14. Bennett AM and Tonks NK: Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science 1997, 278:1288-1291.
15. Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994, 77:841-852.
16. Gredinger E, Gerber AN, Tamir Y, Tapscott SJ, Bengal E: Mitogen-activated protein kinase pathway is involved in the differentiation of muscle cells. J.Biol.Chem. 1998, 273:10436-10444.
17. Tombes RM, Auer KL, Mikkelsen R, Valerie K, Wymann MP, Marshall CJ, McMahon M, Dent P: The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem.J. 1998, 330 (Pt 3):1451-1460.
18. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L: ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003, 63:1684-1695.
19. Chen G, Hitomi M, Han J, Stacey DW: The p38 pathway provides negative feedback for Ras proliferative signaling. J.Biol.Chem. 2000, 275:38973-38980.
20. Todd DE, Densham RM, Molton SA, Balmanno K, Newson C, Weston CR, Garner AP, Scott L, Cook SJ: ERK1/2 and p38 cooperate to induce a p21ClP1-dependent G1 cell cycle arrest. Oncogene 2004, 23:3284-3295.
21. Dagher R and Helman L: Rhabdomyosarcoma: an overview. Oncologist. 1999, 4:34-44.
22. Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K: Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia. 1999, 1:340-348.
23. Tapscott SJ, Thayer MJ, Weintraub H: Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 1993, 259:1450-1453.
24. Barr FG: Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001, 20:5736-5746.
25. Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M: The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am.J.Pathol. 1996, 149:143-151.
26. Knudsen ES, Pazzagli C, Born TL, Bertolaet BL, Knudsen KE, Arden KC, Henry RR, Feramisco JR: Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD. Cancer Res. 1998, 58:2042-2049.
27. Bouche M, Senni MI, Grossi AM, Zappelli F, Polimeni M, Arnold HH, Cossu G, Molinaro M: TPA-induced differentiation of human rhabdomyosarcoma cells: expression of the myogenic regulatory factors. Exp.Cell Res. 1993, 208:209-217.
28. Otten AD, Firpo EJ, Gerber AN, Brody LL, Roberts JM, Tapscott SJ: Inactivation of MyoD-mediated expression of p21 in tumor cell lines. Cell Growth Differ. 1997, 8:1151-1160.
29. Sirri V, Leibovitch MP, Leibovitch SA: Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain. Oncogene 2003, 22:5658-5666.
30. Mauro A, Ciccarelli C, De Cesaris P, Scoglio A, Bouche M, Molinaro M, Aquino A, Zani BM: PKCalpha-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J.Cell Sci. 2002, 115:3587-3599.
31. Chen PL, Scully P, Shew JY, Wang JY, Lee WH: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989, 58:1193-1198.
32. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E: The stress-activated protein kinases p38 alpha and JNK1 stabilize p21 (Cip1) by phosphorylation. J.Biol.Chem. 2002, 277:29792-29802.
33. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW,.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746.
34. Yu R, Mandlekar S, Lei W, Fahl WE, Tan TH, Kong AT: p38 mitogen-activated protein kinase negatively regulates the induction of phase II drugmetabolizing enzymes that detoxify carcinogens. J.Biol.Chem. 2000, 275:2322-2327.
35. Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C, Otterson GA: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21 (Cip1) promoter. Mol.Cell Biol. 2003, 23:4056-4065.
36. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21 (Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18:1223-1234.
37. Chen J, Willingham T, Shuford M, Bruce D, Rushing E, Smith Y, Nisen PD: Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 1996, 13:1395-1403.
38. Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat.Cell Biol. 1999, 1:193-199.
39. Miskimins WK, Wang G, Hawkinson M, Miskimins R: Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol.Cell Biol. 2001, 21:4960-4967.
40. Gysin S, Lee SH, Dean NM, McMahon M: Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res. 2005, 65:4870-4880.
41. Ostrakhovitch EA and Cherian MG: Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: The lack of effect of ERK in p53 mediated copper induced apoptosis. J.Cell Biochem. 2005, 95:1120-1134.
42. Moretti A, Borriello A, Monno F, Criscuolo M, Rosolen A, Esposito G, Dello IR, Delia RF, Iolascon A: Cell division cycle control in embryonal and alveolar rhabdomyosarcomas. Eur.J.Cancer 2002, 38:2290-2299.
43. Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J, Feramisco JR, Karin M, Wang JY: Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev. 2000, 14:574-584.
44. Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F. Feramisco JR, Karin M, Wang JY, Puri PL: p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol.Cell Biol. 2000, 20:3951-3964.
45. Wei Q and Paterson BM: Regulation of MyoD function in the dividing myoblast. FEBS Lett. 2001, 490:171-178.
46. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ: Protein measurement with the Folin phenol reagent. J.Biol.Chem. 1951, 193:265-275.
47. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992, 70:993-1006.
48. Eustice DC, Feldman PA, Colberg-Poley AM, Buckery RM, Neubauer RH: A sensitive method for the detection of beta-galactosidase in transfected mammalian cells. Biotechniques 1991, 11:739-3.
49. Davis RL, Weintraub H, Lassar AB: Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987, 51:987-1000.
50. Wright WE, Sassoon DA, Lin VK: Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell 1989, 56:607-617.
51. Mansour SJ, Candia JM, Gloor KK, Ahn NG: Constitutively active mitogen-activated protein kinase kinase 1 (MAPKK1) and MAPKK2 mediate similar transcriptional and morphological responses. Cell Growth Differ. 1996, 7:243-250.